Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
6.54 (1y: +23%)
Market Cap 354.76 M P/E(ttm)
Enterprise Value 321.37 M P/B
RPTP- NAS (USA)
Raptor Pharmaceutical Corp
Not Rated
Top Ranked Predictable Companies
$6.54
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
» RPTP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

RPTP Guru Trades in Q2 2012

Columbia Wanger 4,520,200 sh (-14.33%)
» More
Q3 2012

RPTP Guru Trades in Q3 2012

Columbia Wanger 3,536,000 sh (-21.77%)
» More
Q4 2012

RPTP Guru Trades in Q4 2012

Columbia Wanger 3,536,000 sh (unchged)
» More
Q1 2013

RPTP Guru Trades in Q1 2013

Columbia Wanger Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RPTP



No Insider Trades Found!

Ratios

vs
industry		 vs
history
EV-to-EBIT 55.6
RPTP's EV-to-EBIT is ranked lower than
273224% of the 366 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.66 vs. RPTP: 55.6 )
RPTP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 55.6

Valuation & Return

vs
industry		 vs
history

Business Description

Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc.'. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. The Company researches, produces, and delivers medicines that improve life for patients with severe, rare disorders. Its product portfolio includes both candidates from its proprietary drug targeting platforms and in-licensed and acquired product candidates. Its current pipeline includes three clinical development programs, which it is actively developing. The Company also has two other clinical-stage product candidates, one of which it is seeking additional business development partners in Asia, but are not internally developing, and it has three pre-clinical product candidates for which it is seeking development partners. The Company's three active clinical development programs are based on an existing therapeutic that it is reformulating for potential improvement in safety and/or efficacy and for application in new disease indications. These clinical development programs include DR Cysteamine, or RP103, for the potential treatment of nephropathic cystinosis, or cystinosis, a rare genetic disorder; and RP103 for the potential treatment of Huntington's Disease, or HD, an inherited neurodegenerative disorder; RP103 is its proprietary delayed-release formulation of cysteamine bitartrate microbeads in capsules, which may require less frequent dosing and reduce gastro-intestinal side effects compared to the current standard of care; RP104, for the potential treatment of non-alcoholic steatohepatitis, or NASH, a metabolic disorder of the liver. RP104 is proprietary delayed-release formulation of cysteamine bitartrate in tablets. Its other clinical-stage product candidates include: Convivia for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2 deficiency, an inherited metabolic disorder; and Tezampanel, a glutamate receptor antagonist as a potential anti-platelet agent, and NGX 426. Its preclinical platforms consist of targeted therapeutics for the potential treatment of multiple indications, including liver diseases, neurodegenerative diseases and breast cancer. It is seeking development partners for these programs. These preclinical programs include its receptor-associated protein, or RAP, platform consists of: HepTide for the potential treatment of primary liver cancer and other liver diseases; and NeuroTrans to potentially deliver therapeutics across the blood-brain barrier for treatment of a variety of neurological diseases. Its mesoderm development protein, or Mesd, platform consists of Wnt
Company Website
SEC Reports
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS
Traded in other countries:XYXR.Germany
» More Articles for RPTP

Headlines

Articles On GuruFocus.com

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial